Investor focus ahead of Q1 earnings

Royalty Pharma (RPRX) heads into Wednesday’s pre-market Q1 earnings release with attention on expectations for 53.8% year-on-year revenue growth, after the company previously reported 4.8% revenue growth and missed analyst revenue forecasts.

Royalty Pharma’s share price has gained 16.8% over the last 90 days and 29.2% year to date, while the 1 year total shareholder return of 55.7% highlights building momentum ahead of the upcoming Q1 report at a last close of $50.20.

If you are looking at how earnings expectations can shift interest across the sector, this is a good moment to scan for potential opportunities in 33 healthcare AI stocks

With the stock up strongly over the past year and trading only slightly below the latest analyst price target, the key question is whether Royalty Pharma is still undervalued or whether the market is already pricing in future growth.

Most Popular Narrative: 2.6% Undervalued

Royalty Pharma’s most followed narrative puts fair value at $51.56, only slightly above the last close at $50.20. This frames earnings expectations tightly around future royalty growth and capital deployment.

Strategic reinvestment of large, stable cash flows into new and increasingly innovative royalty acquisitions, enhanced by improved data-driven diligence and risk management, allows Royalty Pharma to continually expand its portfolio with attractive economics, increasing operating leverage and net margins over time.

Want to see what sits behind that reinvestment pitch? The narrative leans on specific revenue assumptions, shifting margins, and a future earnings multiple that might surprise you.

Result: Fair Value of $51.56 (UNDERVALUED)

However, that upside case still leans heavily on ongoing royalty disputes and exposure to regulatory changes that could shrink royalty pools and pressure earnings expectations.

Another View on Royalty Pharma’s Valuation

The narrative fair value of $51.56 suggests only 2.6% upside from the last close, yet Simply Wall St’s fair ratio work paints a very different picture. On P/E, RPRX trades at 28.9x versus a fair ratio of 19.7x and an industry average of 17x, and also above a 19.9x peer average. This points to a rich valuation rather than a small discount. So, is the story closer to a slight undervaluation or a premium that needs strong execution to hold up?

For a closer look at how this P/E gap could matter for future returns, check the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals so far, with valuation and narratives pulling in different directions, mean this is a moment to look at the data yourself and move quickly to frame your own stance. A good starting point is the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that could suit your style better, so put a few more ideas on your radar.

• Target stronger value potential by scanning companies that combine quality fundamentals with appealing pricing using the 48 high quality undervalued stocks.
• Strengthen your income focus by reviewing stocks that offer 5%+ yields and aim for resilience with the 12 dividend fortresses.
• Prioritise peace of mind by filtering for companies that show resilient profiles using the 70 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.